跳到正文
Urology Times· @UrologyTimes · X·· 2 天前评分70

KEYNOTE-866

正文 · 机器翻译

KEYNOTE-866(#ESMO2026):在新辅助 cisplatin 联合 gemcitabine 方案中加用围手术期 pembrolizumab,未能显著改善适合接受 cisplatin 治疗的 MIBC 患者的无事件生存期。https://www.urologytimes.com/view/adding-perioperative-pembrolizumab-chemotherapy-does-not-improve-efs-mibc

263 浏览 · 1 赞 · 0 转发 · 0 回复

会议摘要
4735O按 Proffered paper 1: Genitourinary tumour, renal and urothelial 对上

Perioperative pembrolizumab (pembro) or placebo (pbo) + neoadjuvant cisplatin (cis) and gemcitabine (gem) in participants (pts) with muscle-invasive bladder cancer (MIBC): the double-blind, phase 3 KEYNOTE-866 study

https://esmocongress.esmo.org

来源:Urology Times · x.com

CBACBA Frontier Insights (CFI)美国华人生物医药科技协会(CBA)www.cba-usa.org